| 表情序长 | 大股票理事 動畫行政人員名 作出技霸的 圓人 / 蒙出或接及的 母版的平均價 | | 持有機量的股份數目 佔已發行的 有關事件的日 相關注體股份優媒證權益 | | --- | --- | --- | --- | | .. 1980 11 | | 投分數目 | 【靖奇卿上班 * 在 | | CARDER CONSULTION CO | | 11 11 21 2 3 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 | STATISTICS COLLECTION OF CLAIMS OF THE FOR CANDRE PORT POST A THE CONSULTION CONSULTI CLASSE | | CS20251113E00042 汇资量基金管理股份有限公司 1101(L) | | 1.471.000(L | HKD 28 4000 146,880,000(L) 6,04(L)10/11/2025 C (r) Michi | 格隆汇11月14日丨根据联交所最新权益披露资料显示，2025年11月10日，三生制药( ...

Group 1 - The Hang Seng Index rose by 0.56% to close at 27,073.03 points on November 13, with a total net sell of 3.52 billion HKD through the southbound trading channel [1] - The total trading amount for the southbound trading on November 13 was 124.97 billion HKD, with a net sell of 3.52 billion HKD [1] - The Shanghai Stock Exchange's southbound trading had a total trading amount of 75.99 billion HKD and a net sell of 2.13 billion HKD, while the Shenzhen Stock Exchange had a total trading amount of 48.98 billion HKD and a net sell of 1.39 billion HKD [1] Group 2 - In the top ten active stocks for the Shanghai Stock Exchange's southbound trading, Alibaba-W had the highest trading amount of 9.91 billion HKD, followed by the Tracker Fund of Hong Kong and SMIC with trading amounts of 4.27 billion HKD and 3.44 billion HKD respectively [2] - Alibaba-W had a net buy amount of 1.70 billion HKD, with its stock price increasing by 3.32% [2] - The Tracker Fund of Hong Kong had the highest net sell amount of 4.26 billion HKD, while its stock price increased by 0.52% [2] Group 3 - In the Shenzhen Stock Exchange's southbound trading, Alibaba-W also led with a trading amount of 5.99 billion HKD, followed by SMIC and Tencent Holdings with trading amounts of 2.61 billion HKD and 2.27 billion HKD respectively [2] - The highest net buy amount was for Huahong Semiconductor at 196 million HKD, with its stock price rising by 5.64% [2] - The highest net sell amount was again for the Tracker Fund of Hong Kong at 196 million HKD, with its stock price increasing by 0.52% [2]

Core Viewpoint - The Hong Kong stock market experienced significant net selling from northbound capital, with a total net sell of 35.21 billion HKD on November 13, 2023, indicating a cautious sentiment among investors [1]. Group 1: Stock Performance - Alibaba-W (09988) saw a net inflow of 16.97 billion HKD, with a total trading volume of 99.09 billion HKD, reflecting strong investor interest [2]. - Xiaomi Group-W (01810) recorded a net inflow of 8.91 billion HKD, indicating positive market sentiment towards its stock [2]. - Tencent (00700) faced a net outflow of 8.68 billion HKD, highlighting investor concerns following its quarterly earnings report [2][6]. Group 2: Sector Trends - Semiconductor stocks, including Hua Hong Semiconductor (01347) and SMIC (00981), received net inflows of 868.1 million HKD and 760.6 million HKD respectively, driven by optimistic forecasts for the AI-driven semiconductor cycle extending until 2027 [5]. - The report from Morgan Stanley predicts global semiconductor revenue growth of 18% and 11% in 2026 and 2027, respectively, supporting the bullish outlook for Asian tech stocks [5]. Group 3: ETF Activity - The Hang Seng Index ETF (02800) and the Hang Seng China Enterprises Index ETF (02828) experienced significant net outflows of 62.26 billion HKD and 22.89 billion HKD, respectively, reflecting a broader market weakness [7]. - Despite the outflows, analysts maintain a cautiously optimistic view on the medium-term market outlook, emphasizing the importance of technology innovation and domestic demand [7].

智通财经APP获悉，香港联交所最新资料显示，11月10日，汇添富基金增持三生制药(01530)147.1万 股，每股均价28.4港元，总金额为4177.64万港元。增持后最新持股数目约为1.47亿股，最新持股比例 6.04%。 ...

香港联交所最新资料显示，11月10日，汇添富基金增持三生制药(01530)147.1万股，每股均价28.4港 元，总金额为4177.64万港元。增持后最新持股数目约为1.47亿股，最新持股比例6.04%。 ...

Core Insights - On November 13, 2025, Alibaba-W (09988), the Tracker Fund of Hong Kong (02800), and SMIC (00981) were the top three stocks by trading volume in the Southbound Stock Connect, with trading amounts of 99.09 billion, 42.74 billion, and 34.39 billion respectively [1] - In the Shenzhen-Hong Kong Stock Connect, Alibaba-W (09988), SMIC (00981), and Tencent Holdings (00700) led the trading volume, with amounts of 59.89 billion, 26.06 billion, and 22.68 billion respectively [1] Southbound Stock Connect Top Active Companies - Alibaba-W (09988) had a trading amount of 99.09 billion with a net buying amount of +16.97 billion [2] - The Tracker Fund of Hong Kong (02800) recorded a trading amount of 42.74 billion with a net buying amount of -42.64 billion [2] - SMIC (00981) had a trading amount of 34.39 billion with a net buying amount of +4.71 billion [2] - Tencent Holdings (00700) had a trading amount of 31.35 billion with a net buying amount of -8.68 billion [2] - Xiaomi Group-W (01810) recorded a trading amount of 23.28 billion with a net buying amount of +8.91 billion [2] Shenzhen-Hong Kong Stock Connect Top Active Companies - Alibaba-W (09988) had a trading amount of 59.89 billion with a net buying amount of -3.23 billion [2] - SMIC (00981) recorded a trading amount of 26.06 billion with a net buying amount of -3.95 billion [2] - Tencent Holdings (00700) had a trading amount of 22.68 billion with a net buying amount of -679.98 million [2] - The Tracker Fund of Hong Kong (02800) recorded a trading amount of 19.73 billion with a net buying amount of -19.62 billion [2] - Xiaomi Group-W (01810) had a trading amount of 16.81 billion with a net buying amount of -1.11 billion [2]

Core Viewpoint - The Hong Kong innovative drug sector is experiencing strong performance, with significant stock price increases for several companies in the industry [1] Company Performance - Sanofi Pharmaceutical (01530.HK) increased by 10.11%, reaching HKD 33.76 [1] - Innovent Biologics (02096.HK) rose by 7.52%, trading at HKD 14.02 [1] - BeiGene (06160.HK) saw a 7.34% increase, with shares priced at HKD 228.2 [1] - China Biologic Products (01177.HK) gained 6.79%, now at HKD 7.39 [1] - I-Mab (01801.HK) experienced a 6.37% rise, with shares at HKD 92.7 [1]

Group 1 - The innovative drug sector has shown strong performance, with notable stock increases for companies such as Sangamo Therapeutics (up 10.11%), Innovent Biologics (up 7.52%), BeiGene (up 7.34%), China Biologic Products (up 6.79%), and I-Mab (up 6.37%) [1] - In Q3, the innovative drug sector reported a revenue growth of 1.98% year-on-year and a net profit attributable to the parent company increased by 7.25% year-on-year [1] - Despite adjustments since September, the overall trend for the innovative drug industry remains positive, supported by domestic policy and the Federal Reserve entering a rate-cutting cycle, with a significant number of licensing deals expected in the next six months to a year [1] Group 2 - Guotai Junan Securities noted that the innovative drug sector continued to experience high revenue growth and profitability turnaround in Q3, indicating a long-term positive development trend for China's innovative drug industry [2] - The explosive growth in business development (BD) transactions has been a key highlight in recent years for the domestic innovative drug sector [2] - For most domestic innovative drugs, external licensing is often just the starting point for global development, with the progress of partners in overseas development and subsequent global clinical data readings enhancing the commercial certainty of products in the global market [2]

Group 1 - The innovative drug sector shows strong performance, with notable stock price increases for companies such as 三生制药 (up 10.11%), 先声药业 (up 7.52%), and 百济神州 (up 7.34%) [1] - In Q3, the innovative drug sector's revenue grew by 1.98% year-on-year, while net profit attributable to shareholders increased by 7.25% year-on-year [1] - Despite adjustments since September, the overall trend for the innovative drug industry remains positive, supported by domestic policies and the Federal Reserve entering a rate-cutting cycle [1] Group 2 - The innovative drug sector continued to experience high revenue growth and profitability turnaround in Q3, indicating a long-term positive development trend [2] - The surge in business development (BD) transactions highlights the growth potential of the Chinese innovative drug industry [2] - For most domestic innovative drugs, external licensing is often just the starting point for global development, with subsequent clinical data enhancing commercial certainty in global markets [2]

此外，辉瑞公布707全球临床策略，第一波近期临床试验的核心为两项3期关键临床 (NSCLC1L;mCRC1L)，并将于近期启动5项研究，包括：ES-SCLC1L的ph2/3研究，NSCLC中联合ADCs 的ph1/2研究，mHCC的ph1/2研究，mUC的ph1/2研究和mRCC的ph1/2研究。辉瑞的第二波开发计划预计 在2026年底前将新增10个适应症的临床试验和10种以上新型组合方案，目标用707替代现有标准治疗的 PD-(L)1抑制剂和VEGF抑制剂，成为新的基石疗法;同时探索与ADC的联用，开发无化疗方案，并将其 应用拓展至新辅助治疗和辅助治疗等早期治疗场景。 报告中称，近日，三生制药在STIC会议上公布707联合化疗治疗1LNSCLC的临床2期研究数据，数据显 示707联合化疗在sqNSCLC和nsqNSCLC中均具备良好的有效性和安全性，支持707联合化疗继续在 1LNSCLC中开展临床3期研究 国信证券发布研报称，三生制药(01530)创新药临床快速推进，完成重磅对外授权交易，业绩保持稳健 增长。考虑到707对外授权已经落地，该行上调盈利预测，预计2025-2027年公司的归母净利润为 99. ...